These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6795911)

  • 1. Electrophysiologic evaluation of encainide with use of monophasic action potential recording.
    Samuelsson RG; Harrison DC
    Am J Cardiol; 1981 Nov; 48(5):871-6. PubMed ID: 6795911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canine electrophysiology of encainide, a new antiarrhythmic drug.
    Sami M; Mason JW; Oh G; Harrison DC
    Am J Cardiol; 1979 Jun; 43(6):1149-54. PubMed ID: 443174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiologic actions of O-demethyl encainide: an active metabolite.
    Duff HJ; Dawson AK; Roden DM; Oates JA; Smith RF; Woosley RL
    Circulation; 1983 Aug; 68(2):385-91. PubMed ID: 6861313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophysiologic effects of encainide following acute coronary occlusion in dogs.
    Ro JH; Gillon J; Kupersmith J
    J Cardiovasc Pharmacol; 1981; 3(3):532-40. PubMed ID: 6168834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical electrophysiologic effects of encainide, a newly developed antiarrhythmic agent.
    Sami M; Mason JW; Peters F; Harrison DC
    Am J Cardiol; 1979 Sep; 44(3):526-32. PubMed ID: 474433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiology of oral encainide.
    Jackman WM; Zipes DP; Naccarelli GV; Rinkenberger RL; Heger JJ; Prystowsky EN
    Am J Cardiol; 1982 Apr; 49(5):1270-8. PubMed ID: 6801954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Qualitative and quantitative comparison of the cardiac effects of encainide and its three major metabolites in the dog.
    Davy JM; Dorian P; Kantelip JP; Harrison DC; Kates RE
    J Pharmacol Exp Ther; 1986 Jun; 237(3):907-11. PubMed ID: 3086540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic and electrophysiologic effects of encainide in patients with bundle branch block.
    Schwartz AB; Shapiro WA; Suave MJ; Shen E; Bhandari A; Morady F; Scheinman M
    Can J Cardiol; 1987 Mar; 3(2):75-82. PubMed ID: 3105850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of encainide (MJ9067) on the ventricular fibrillation threshold in anesthetized dogs.
    Jaillon P; de la Rosa S; Griffin JC; Winkle RA; Harrison DC
    J Cardiovasc Pharmacol; 1980; 2(5):517-26. PubMed ID: 6157946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of encainide and its two major metabolites on cardiac conduction.
    Dresel PE
    J Pharmacol Exp Ther; 1984 Jan; 228(1):180-6. PubMed ID: 6420542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide.
    Buchanan LV; Kabell G; Turcotte UM; Brunden MN; Gibson JK
    J Cardiovasc Pharmacol; 1992 Feb; 19(2):256-63. PubMed ID: 1376795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide.
    Bajaj AK; Woosley RL; Roden DM
    Circulation; 1989 Oct; 80(4):994-1002. PubMed ID: 2551538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers.
    Turgeon J; Funck-Brentano C; Gray HT; Pavlou HN; Prakash C; Blair IA; Roden DM
    Clin Pharmacol Ther; 1991 May; 49(5):488-96. PubMed ID: 1903098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of encainide and metabolites (MJ14030 and MJ9444) on canine cardiac Purkinje and ventricular fibers.
    Elharrar V; Zipes DP
    J Pharmacol Exp Ther; 1982 Feb; 220(2):440-7. PubMed ID: 6799644
    [No Abstract]   [Full Text] [Related]  

  • 15. Electrophysiologic effects of encainide on acutely ischemic rabbit myocardial cells.
    Wong SS; Myerburg RJ; Ezrin AM; Gelband H; Bassett AL
    Eur J Pharmacol; 1982 Jun; 80(4):323-9. PubMed ID: 6809479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encainide.
    Antonaccio MJ; Gomoll AW; Byrne JE
    Cardiovasc Drugs Ther; 1989 Oct; 3(5):691-710. PubMed ID: 2518680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electropharmacodynamics of N-acetylprocainamide in the immature mammalian heart--evidence for a prominent class III effect in the newborn.
    Dise T; Stolfi A; Yamasaki S; Pickoff AS
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):96-101. PubMed ID: 1708063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophysiological effects of encainide and its metabolites in 11 patients.
    Libersa CC; Lekieffre JP; Caron JF; Poirier JM; Pladys AM; Kacet S; Kher AR
    J Cardiovasc Pharmacol; 1985; 7(6):1077-82. PubMed ID: 2418291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of encainide and its metabolites on energy requirements for defibrillation.
    Fain ES; Dorian P; Davy JM; Kates RE; Winkle RA
    Circulation; 1986 Jun; 73(6):1334-41. PubMed ID: 3084128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encainide: a new and potent antiarrhythmic agent.
    Harrison DC; Winkle R; Sami M; Mason J
    Am Heart J; 1980 Dec; 100(6 Pt 2):1046-54. PubMed ID: 6778194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.